Oscar Health (NYSE: OSCR) taps Sankaran as chair, keeps 2026 outlook
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Oscar Health, Inc. reaffirmed its full year 2026 guidance that was originally provided with its fourth quarter and full year 2025 results. The company also reminded investors it plans to release first quarter 2026 financial results before the market opens on May 6, 2026, followed by a conference call at 8:00 AM (ET).
Oscar announced that independent director Siddhartha Sankaran will become Chair of the Board effective June 4, 2026, succeeding Jeffery Boyd, who is not standing for reelection at the upcoming annual meeting. The company highlights Sankaran’s extensive insurance industry and board experience, and both Boyd and Sankaran emphasize Oscar’s positioning for future growth and its role in the individual health insurance market.
Positive
- None.
Negative
- None.
Insights
Oscar reaffirms 2026 outlook and transitions to a new independent Board chair.
Oscar Health confirms that its previously issued full year 2026 guidance remains intact, signaling no change in management’s expectations ahead of first quarter 2026 results. This is framed as a reassurance to the market rather than a revision of prior targets.
The company is also elevating independent director Siddhartha Sankaran to Chair of the Board, effective June 4, 2026, as long-serving chair Jeffery Boyd steps down and does not stand for reelection. The filing underscores Sankaran’s deep insurance background and governance experience, suggesting continuity in strategic oversight rather than a shift in direction.
From an investor perspective, the combination of stable guidance and a planned, experience-based leadership handoff at the Board level appears orderly. The real test of the reaffirmed outlook will come when Oscar reports first quarter 2026 results on May 6, 2026 and discusses performance against the 2026 plan.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Terms
Regulation FD Disclosure, forward-looking statements, Annual Report on Form 10-K, Private Securities Litigation Reform Act of 1995, +2 more
6 terms
Regulation FD Disclosure regulatory
"Item 7.01. Regulation FD Disclosure. Guidance Reaffirmation Oscar Health, Inc."
forward-looking statements regulatory
"This on contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Annual Report on Form 10-K regulatory
"the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025"
An annual report on Form 10‑K is a required, comprehensive filing that publicly traded companies give to regulators and investors summarizing their business, results of operations, detailed financial statements reviewed by independent auditors, material risks, legal issues and management’s discussion of performance. Investors use it like a company’s year‑end report card and medical checkup: it reveals how the business made money, where it is vulnerable, and the facts needed to compare value, judge risk and make informed investment decisions.
Private Securities Litigation Reform Act of 1995 regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
individual market financial
"It’s been a privilege to be a part of Oscar’s transformation from bold startup into a leader in the individual market."
healthcare technology company technical
"Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced the appointment"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 21, 2026
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of Principal Executive Offices) (Zip Code)
(646 ) 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. Regulation FD Disclosure.
Guidance Reaffirmation
Oscar Health, Inc. (the “Company”), in advance of its upcoming participation in the Medicarians 2026 conference on April 21, 2026, is reaffirming the full year 2026 guidance that it provided in its financial results press release for the fourth quarter and full year 2025 dated February 10, 2026.
As previously announced, the Company expects to release first quarter 2026 financial results before the market opens on Wednesday, May 6, 2026, and host a conference call to review results beginning at 8:00 AM (ET).
Board Leadership Updates
On April 21, 2026, the Company issued a press release announcing upcoming changes to its Board leadership. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
This information (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our expected financial performance, upcoming events and presentations, and Board leadership structure. Accordingly, we caution you that any such forward-looking statements are not guarantees and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our ability to execute our strategy and manage our growth effectively (including our ability to successfully integrate strategic acquisitions); our ability to retain and expand our member base; our ability to accurately estimate our incurred medical expenses or overall market morbidity, or effectively manage our medical costs or related administrative costs; unanticipated results of, or changes to, risk adjustment programs or our estimates thereof; evolving federal or state laws or regulations (including any changes in the interpretation or enforcement of existing laws and regulations), including changes with respect to the Patient Protection and Affordable Care Act and any regulations enacted thereunder, the expiration of the enhanced Advanced Premium Tax Credits , the implementation of new program integrity rules, the potential funding of a cost-sharing reduction program, or other government actions, such as the imposition of tariffs; our ability to achieve or maintain profitability in the future; our ability to arrange for the delivery of quality care and maintain good relations with brokers and the physicians, hospitals, and other providers within and outside our provider networks; our ability to comply with ongoing, complex and evolving regulatory requirements, including capital reserve and surplus requirements and applicable performance standards; changes or developments in the regulation of health insurance markets in the United States; our, or any of our vendors’, ability to comply with laws, regulations, and standards related to the handling of information about individuals or applicable consumer protection laws, including as a result of our participation in government-sponsored programs; the ability of our health insurance and Health Maintenance Organization subsidiaries to make payments of dividends or distributions to us, including to fund our business strategy; our ability to utilize quota share reinsurance to meet our capital and surplus requirements and protect against downside risk on medical claims; adverse market conditions resulting in our investment portfolio suffering losses or reducing our ability to meet our financing needs; unfavorable or otherwise costly outcomes of lawsuits, audits, investigations, and other third party claims that may arise from the extensive laws and regulations to which we are subject; incurrence of data security breaches of our or our partners’ information and technology systems;
heightened competition in the markets in which we participate; our ability to attract and retain qualified personnel; uncertainties associated with our utilization of certain artificial intelligence and machine learning models; our ability to detect and prevent material weaknesses or significant control deficiencies in our internal controls over financial reporting or other failure to maintain an effective system of internal controls; adverse publicity or other adverse consequences related to our dual class structure or “controlled company” status; and the other factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC.
You are cautioned not to place undue reliance on any forward-looking statements made in this Form 8-K. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Press Release, dated April 21, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Oscar Health, Inc. | |||||||||||
| By: | /s/ R. Scott Blackley | ||||||||||
| Name: | R. Scott Blackley | ||||||||||
| Title: | Chief Financial Officer | ||||||||||
Date: April 21, 2026
 | |||||
Oscar Health, Inc. ir.hioscar.com News Release | |||||
NEW YORK – April 21, 2026 – Oscar Health, Inc. (“Oscar” or the “Company”) (NYSE: OSCR), a leading healthcare technology company, today announced the appointment of independent director Siddhartha Sankaran as Chair of the Board, effective June 4, 2026. Sankaran will succeed Jeffery Boyd, who has served as Chair since February 2021 and is not standing for reelection at Oscar Health’s Annual Meeting.
Sankaran has more than 20 years of leadership in the insurance industry, serving in executive roles at multiple public companies, including at American International Group, Inc., SiriusPoint Ltd and FWD Group Holdings Limited. He brings a wealth of expertise from serving on numerous boards. He also contributed to building robust governance practices and standards in his five years of service on Oscar Health’s Board.
Mark Bertolini, Oscar Health’s Chief Executive Officer, said: "The individual market is the future of healthcare for millions of consumers and businesses. I am thrilled to have Sid lead our Board through Oscar’s next phase. I also want to thank Jeff for his tireless commitment, first as a trusted advisor and through our IPO and beyond. His steady leadership was instrumental during a defining period of growth and change.”
Boyd remarked: “It’s been a privilege to be a part of Oscar’s transformation from bold startup into a leader in the individual market. The past 12 years have been an incredible run. Oscar is positioned for strong 2026 performance and long-term growth, and could not be in better hands as I begin my next chapter.”
Sankaran added: “I am honored to step into this role at a pivotal moment for Oscar and for healthcare. The future of healthcare should be simple, personal, and consumer-driven – and Oscar is uniquely positioned to lead that change. The Oscar team is redefining the healthcare experience and building a more efficient market that works for everyone.”
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our business and financial prospects, and industry and market dynamics and expected trends. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “predicts,” “potential,” or “continues” or the negative of these terms or other similar expressions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control.
Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the factors set forth under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”), and our other filings with the SEC.
You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law,
we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.
About Oscar Health
Oscar Health, Inc. is a leading healthcare technology company built on a full-stack platform and a relentless focus on member experience. Oscar Health helps make high-quality and affordable care more accessible for millions of people through Oscar’s Individual & Family plans and ICHRA solutions, +Oscar technology services, and Lucie Health Marketplace. Consumers benefit from better choice, deeper engagement, and connection to high-value clinical care
Investor Contact:
Chris Potochar
VP of Investor Relations
ir@hioscar.com
Chris Potochar
VP of Investor Relations
ir@hioscar.com
Media Contact:
Dalya Browne
Senior Director, Communications
press@hioscar.com
Dalya Browne
Senior Director, Communications
press@hioscar.com
FAQ
What guidance did Oscar Health (OSCR) reaffirm in this 8-K?
Oscar Health reaffirmed its full year 2026 guidance, confirming the same financial outlook it originally provided with its fourth quarter and full year 2025 results. This indicates management’s expectations for 2026 performance are unchanged heading into the first quarter 2026 earnings release.
When will Oscar Health (OSCR) report its first quarter 2026 results?
Oscar Health expects to release first quarter 2026 financial results before the market opens on May 6, 2026. Management will host a conference call to review the results the same day, beginning at 8:00 AM Eastern Time for analysts and investors.
What Board leadership change did Oscar Health (OSCR) announce?
Oscar Health announced that independent director Siddhartha Sankaran will become Chair of the Board effective June 4, 2026. He will succeed Jeffery Boyd, who has served as Chair since 2021 and is not standing for reelection at the company’s upcoming annual shareholder meeting.
Who is Siddhartha Sankaran, the new Chair of Oscar Health’s Board?
Siddhartha Sankaran is an independent director with more than 20 years of leadership in the insurance industry. He has held executive roles at several public companies, served on multiple boards, and spent five years on Oscar Health’s Board contributing to its governance practices.
Why is Jeffery Boyd leaving the Chair role at Oscar Health (OSCR)?
Jeffery Boyd, who has served as Chair of Oscar Health’s Board since February 2021, is not standing for reelection at the company’s annual meeting. He highlighted pride in Oscar’s transformation and expressed confidence in the company’s positioning for strong 2026 performance and long-term growth.
What risks and forward-looking statement cautions does Oscar Health (OSCR) highlight?
Oscar Health notes that its forward-looking statements, including expectations for financial performance and market trends, involve risks and uncertainties. It cites factors such as regulatory changes, medical cost estimation, competitive dynamics, capital requirements, technology risks, and items described under “Risk Factors” in its Form 10-K.